Bavencio becomes first treatment for rare skin cancer mMCC licensed for use in the UK

7 Nov 2017

The launch of avelumab marks a step-change in the way that mMCC can be treated.

Merck and Pfizer have announced the UK launch of Bavenio (avelumab) solution for infusion 20 mg/mL, as a monotherapy for the treatment of mMCC in adults. Avelumab is the first medicine to be licensed for this rare, aggressive type of skin cancer.

Bavencio becomes first treatment for rare skin cancer mMCC licensed for use in the UK

“The licensing of avelumuab in this disease is an advance for patients as it is well tolerated, and active,” commented Professor Ruth Plummer, Consultant Medical Oncologist at the Newcastle upon Tyne Hospitals NHS Foundation Trust. “Patients with mMCC are often elderly and find our standard chemotherapy hard going, needing dose reductions or breaks from treatment.”

The incidence of mMCC is so low that it is hard to be accurate; it is thought, however, that there are approximately 50 new cases of mMCC annually in the UK. However, data show that the incidence of MCC is rising possibly due to an ageing population or increased UV exposure. MCC exhibits aggressive clinical features, including frequent lymph node involvement and early metastases. Patients with mMCC have a very poor prognosis, with fewer than half of patients surviving more than one year and fewer than 20% surviving beyond 5 years.

While earlier-stage MCC can be generally managed with surgery and radiotherapy, treatment options for mMCC are severely limited. Until now, there have been no licensed medicines to treat mMCC in the UK. As such, the standard of care for patients with mMCC is to enrol in clinical trials.

The efficacy and safety of avelumab was demonstrated in the JAVELIN Merkel 200 trial, an international, multicentre, single-arm, open-label, Phase II study with two parts (still ongoing):

  • Part A15,16 included 88 patients with mMCC whose disease had progressed after at least one chemotherapy treatment. The objective response rate was 33%, with 11% of patients experiencing a complete response and 22% of patients experiencing a partial response. Responses were noted at the time of the first post-baseline tumour assessment (week 7) in 22 (76%) of 29 patients. At the time of analysis, tumour responses were durable, with 93% of responses lasting at least 6 months and 71% of responses lasting at least 12 months. The overall survival rate at 6 months was 69%.
  • Part B (still enrolling), at the time of the data cut-off (March 2017), included 39 patients with histologically confirmed mMCC who were treatment-naïve to systemic therapy in the metastatic setting. The objective response rate was 62%, with 14% of patients experiencing a complete response (CR) and 48% of patients experiencing a partial response (PR). 16 of 18 confirmed responses (88.9%) occurred approximately 6 weeks after treatment initiation.
  • Avelumab was well tolerated in line with the overall safety database. Most AEs related to treatment were low grade, including all infusion reactions.
  • “We’re really encouraged by the news that avelumab is now licensed for use in the UK,” commented Catherine Bouvier, CEO of the NET Patient Foundation. “Although rare, mMCC is an aggressive cancer with potentially worse outcomes than other types of skin cancer such as melanoma. An effective, well-tolerated treatment option will be welcomed with open arms by patients with mMCC and their families, so we hope that all stakeholders will work in a collaborative way to ensure that patients in the UK now have access to it as quickly as possible.”

    “Today is a significant milestone for the Alliance between Merck and Pfizer,” commented Dr Belinda Byrne, Medical Director at Merck, UK. “It demonstrates our commitment to working in partnership to develop new treatment options for patients with hard-to-treat cancers and we are looking forward to exploring future potential monotherapy indications and a diverse range of novel combinations with avelumab.”

    Read More

    Related tags

    Research & Development

    Related news

    Spanish CDMO working ahead of EU serialisation deadline

    Spanish CDMO working ahead of EU serialisation deadline

    6 Dec 2018

    Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

    Read more 
    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    5 Dec 2018

    The financing will power the global commercial launch of the company's Fluidity One system.

    Read more 
    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    4 Dec 2018

    The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

    Read more 
    NIH to evaluate effectiveness of male contraceptive skin gel

    NIH to evaluate effectiveness of male contraceptive skin gel

    28 Nov 2018

    The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

    Read more 
    QPS expands US-based Phase I clinical trial capabilities

    QPS expands US-based Phase I clinical trial capabilities

    27 Nov 2018

    Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

    Read more 
    Grant winners to investigate continuous manufacturing for gene therapies

    Grant winners to investigate continuous manufacturing for gene therapies

    26 Nov 2018

    Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.

    Read more 
    Proprietary nasal delivery formulation of diazepam reaches NDA

    Proprietary nasal delivery formulation of diazepam reaches NDA

    7 Nov 2018

    The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

    Read more 
    Plasticell receives EU funding to advance neurodegenerative disease research

    Plasticell receives EU funding to advance neurodegenerative disease research

    1 Nov 2018

    Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

    Read more 
    Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

    Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

    30 Oct 2018

    Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

    Read more 
    SIRIO Pharma opens multimillion gummy production plant

    SIRIO Pharma opens multimillion gummy production plant

    18 Oct 2018

    The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

    Read more